^
    over1year
    Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov)
    P2, N=21, Completed, Zhejiang Cancer Hospital | Active, not recruiting --> Completed
    Trial completion • Tumor mutational burden • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    over1year
    Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Zhejiang Cancer Hospital | Trial completion date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    almost2years
    Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Zhejiang Cancer Hospital | Trial completion date: Jun 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
    Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)